While we have taken yet another approach to assessing the contribution of AMPK to atherogenesis (PCSK9-induced atherosclerosis and deletion of both myeloid AMPKα1 and AMPKα2), future work should concentrate on dissecting the specific molecular and metabolic pathways by which this important regulator may act. This evidence concerns the gene PRKAA2 and atherosclerosis.